Search results
Results from the WOW.Com Content Network
Roche shares opened up 1.75%, hitting a six-week high on optimism that the weight-loss market will accommodate many rivals. ... Carmot's employees will join Roche's pharmaceuticals division when ...
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Roche acquired Syntex in 1994, and Chugai Pharmaceuticals in 2002. Oseltamivir an antiviral drug used to combat influenza. Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences. Roche purchased the rights to the drug in 1996, and in 2005, settled a royalty dispute, agreeing to pay Gilead ...
Roche is among a growing number of would-be rivals to Novo and Eli Lilly, whose weight-loss injections have been in feverish demand, with experts boosting their sales forecasts for such treatments ...
Side effects data that Roche released on Monday on another early Carmot project, injection CT-388, had also weighed on its shares, for a 5.4% decline so far this week.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
Save yourself time when sending the same email to multiple people by creating a group of your contacts. Instead of adding each email address separately, you can email a bunch of contacts by typing your group's name in the "To" field of a new email. Once you've created a group, you can continue to add, edit, or delete contacts from it. Add a group
Roche is open to making big acquisitions if they make "sense", Chief Executive Thomas Schinecker said, with the Swiss drugmaker unencumbered by its $20.7 billion deal last year to buy back its ...